Successfully Address Mechanistic, Pharmacological & Specificity Challenges of GPCRs to Discovery & Develop Novel Disease Modifying Therapeutics for Unmet Clinical Needs
May 20-22, 2025 | Boston, MA
Welcome to the 4th GPCR-Targeted Drug Discovery Summit
Transforming the Discovery of Novel GPCR-Targeted Therapies
With positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs, from small molecules to therapeutic proteins and antibodies.
The 4th GPCRs-Targeted Drug Discovery Summit is returning to Boston to showcase the hottest targets of interest, mechanism of action of new GPCR ligands, cutting-edge computational tools to identify high-potential candidates, and effective translational strategies to drive forward discovery & development pipelines to patients in need.
What's in Store for 2025?
Novel Modalities Beyond Small Molecules: Unpack the different modalities that can be employed to target different GPCRs and develop more effective & feasible therapeutics, with coverage of antibodies, peptides, ASOs, degraders and more
Successfully Navigate from Discovery to the Clinic: Overcome challenges in each phase of development to de-risk your programmes and safely translate safe and effective GPCR drugs for a wide range of indications, including diabetes, obesity and CNS disorders
11+ Brand New Organizations Joining the Speaker Faculty: Gain fresh insights and explore new data through the expert speaker panel, made up of leaders from Discovery, Biology and Chemistry, including brand new companies like Abalone Bio, Biolexis Therapeutics and Structure Therapeutics speaking for the first time
Snapshot of Our Speakers:
Jean-Philippe Fortin
Senior Director & Head of Scientific Pharmacology Internal Medicine Research Unit
Pfizer
Our 2025 Partners:
Hear from Previous Attendees:
“Having attended this conference twice, I can confidently say it is a valuable platform for anyone involved in GPCR-targeted drug discovery. For me, it has greatly expanded my understanding of how structural biology is applied to drug discovery, highlighting important technological advancements in academia and the best practices adopted by leading companies".
Xianqiang Song, Director of Structural Biology Technology Platform, Structure Therapeutics
“This meeting is a great opportunity to dive into the latest in GPCR research, like AI-driven discovery and design of different therapeutic modalities and research on orphan receptors and undrugged targets".
Ximena Barros Alvarez, Senior Scientist - Membrane Protein Biochemistry, Tectonic Therapeutics
Other Events in the Small Molecules & TPD World Series:
